IL2 and neoplasm: Key immune cells, including lymphocytes, macrophages, and cytotoxic T cells, target tumor-specific antigens, driving the development of therapies such as granulocyte colony-stimulating factor, interferons, and investigational agents like IL-2 and chemokines, which are advancing through clinical trials (5, 6).